Dr. Clark Y. Lin is a partner in Wilson Sonsini Goodrich & Rosati's New York office. He practices intellectual property law, with an emphasis on patent prosecution, general intellectual property counseling, and intellectual property litigation. Clark focuses on developing, managing, and leveraging global patent portfolios for life science companies. His patent expertise includes the fields of immunotherapies, specialty pharmaceuticals, antibody and protein therapeutics, gene therapies, cell therapies, CRISPR gene editing and RNA therapies. With experience in over 20 issuer-side public offerings, Clark also assists life science companies through the IPO process from an intellectual property perspective.
While in graduate school, Clark investigated signal transduction of intracellular pathways involved in cellular proliferation, differentiation, programmed death, and stress response. Prior to joining the firm, Clark interned as a law clerk for the Washington State Office of the Attorney General and for the University of Washington Office of Technology Transfer, where he worked on a variety of intellectual property matters, including trademark enforcement, software license agreement drafting, copyright infringement, and evaluations of university research for IP protection.
Dr. Clark Y. Lin is a partner in Wilson Sonsini Goodrich & Rosati's New York office. He practices intellectual property law, with an emphasis on patent prosecution, general intellectual property counseling, and intellectual property litigation. Clark focuses on developing, managing, and leveraging global patent portfolios for life science companies. His patent expertise includes the fields of immunotherapies, specialty pharmaceuticals, antibody and protein therapeutics, gene therapies, cell therapies, CRISPR gene editing and RNA therapies. With experience in over 20 issuer-side public offerings, Clark also assists life science companies through the IPO process from an intellectual property perspective.
While in graduate school, Clark investigated signal transduction of intracellular pathways involved in cellular proliferation, differentiation, programmed death, and stress response. Prior to joining the firm, Clark interned as a law clerk for the Washington State Office of the Attorney General and for the University of Washington Office of Technology Transfer, where he worked on a variety of intellectual property matters, including trademark enforcement, software license agreement drafting, copyright infringement, and evaluations of university research for IP protection.
- J.D., University of Washington School of Law, 2008
- Ph.D., Neurobiology, Pharmacology & Physiology, University of Chicago, 2005
- B.A., Molecular & Cell Biology and Music, University of California, Berkeley, 1997
- Named one of “Top 25 Attorneys of Massachusetts for 2022” for his practice in intellectual property law and his emphasis on patent prosecution and general IP counseling
- State Bar of California
- State Bar of Massachusetts
- State Bar of New York
- U.S. Patent and Trademark Office
- J.D., University of Washington School of Law, 2008
- Ph.D., Neurobiology, Pharmacology & Physiology, University of Chicago, 2005
- B.A., Molecular & Cell Biology and Music, University of California, Berkeley, 1997
- Named one of “Top 25 Attorneys of Massachusetts for 2022” for his practice in intellectual property law and his emphasis on patent prosecution and general IP counseling
- State Bar of California
- State Bar of Massachusetts
- State Bar of New York
- U.S. Patent and Trademark Office
Select Publications
-
Author, “PTAB Determines Broad Has Priority in Dispute over CRISPR Gene Editing Patents in Eukaryotic Systems.” Wilson Sonsini Alert, March 2, 2022
-
Co-author with H. Gao and L. Lieto, ”Massachusetts State Senator Files Second Attempt at Bill to Address Bad Faith Patent Infringement Assertions," Intellectual Property & tech Law Journal, 31(7), July 2019
-
Co-author with L. Westin, J. Guise, D. Carsten, V. Norviel, ”District Court Denies Amgen’s Bid to Block Sale of Blockbuster Biosimilar Drug," WSGR Alert, March 19, 2015
-
Co-author with V. Norviel, “The Effects of Government Grant Applications on the Patentability of Life Sciences Technologies,” The Life Sciences Report, Spring 2010, 9-10
- Co-author with B. Franco and M.R. Rosner, "CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders," 14(24) Human Molecular Genetics 3775-86, 2005
- Co-author with Z. Qian, R. Espinosa, M. LeBeau, and M.R. Rosner, "Cloning and Characterization of MST4, a novel Ste-20-like kinase," 276(25) Journal of Biological Chemistry 22439-45, 2001
Select Speaking Engagements
- Speaker, ”Third-Party Intellectual Property and Disputes,” Innovator’s Edge Series, Aug 2021
- Speaker, “IP 101, The Basics for Biotech & Life Science Startups,” Tufts Launchpad | Biolabs, Oct 2018
Select Publications
-
Author, “PTAB Determines Broad Has Priority in Dispute over CRISPR Gene Editing Patents in Eukaryotic Systems.” Wilson Sonsini Alert, March 2, 2022
-
Co-author with H. Gao and L. Lieto, ”Massachusetts State Senator Files Second Attempt at Bill to Address Bad Faith Patent Infringement Assertions," Intellectual Property & tech Law Journal, 31(7), July 2019
-
Co-author with L. Westin, J. Guise, D. Carsten, V. Norviel, ”District Court Denies Amgen’s Bid to Block Sale of Blockbuster Biosimilar Drug," WSGR Alert, March 19, 2015
-
Co-author with V. Norviel, “The Effects of Government Grant Applications on the Patentability of Life Sciences Technologies,” The Life Sciences Report, Spring 2010, 9-10
- Co-author with B. Franco and M.R. Rosner, "CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders," 14(24) Human Molecular Genetics 3775-86, 2005
- Co-author with Z. Qian, R. Espinosa, M. LeBeau, and M.R. Rosner, "Cloning and Characterization of MST4, a novel Ste-20-like kinase," 276(25) Journal of Biological Chemistry 22439-45, 2001
Select Speaking Engagements
- Speaker, ”Third-Party Intellectual Property and Disputes,” Innovator’s Edge Series, Aug 2021
- Speaker, “IP 101, The Basics for Biotech & Life Science Startups,” Tufts Launchpad | Biolabs, Oct 2018
The upsized public offering includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
The Wilson Sonsini team that advised Prime Medicine on IP matters related to the transaction included Lou Lieto, Clark Lin, Rachna Ujwal, Esther Cynn, and David Stanton.
For more information please see Prime Medicine’s press release.
- Privacy Policy
- Terms of Use
- Accessibility